Martin Dreyling
Martin Dreyling
Professor of Medicine, University of Munich
Verified email at med.uni-muenchen.de
Title
Cited by
Cited by
Year
Revised response criteria for malignant lymphoma
BD Cheson, B Pfistner, ME Juweid, RD Gascoyne, L Specht, SJ Horning, ...
Journal of clinical oncology 25 (5), 579-586, 2007
45962007
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients …
W Hiddemann, M Kneba, M Dreyling, N Schmitz, E Lengfelder, R Schmits, ...
Blood 106 (12), 3725-3732, 2005
15392005
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
ML Wang, S Rule, P Martin, A Goy, R Auer, BS Kahl, W Jurczak, ...
New England Journal of Medicine 369 (6), 507-516, 2013
14452013
PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma
AK Gopal, BS Kahl, S De Vos, ND Wagner-Johnston, SJ Schuster, ...
New England Journal of Medicine 370 (11), 1008-1018, 2014
9692014
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
E Hoster, M Dreyling, W Klapper, C Gisselbrecht, A Van Hoof, ...
Blood, The Journal of the American Society of Hematology 111 (2), 558-565, 2008
8882008
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B Eichhorst, T Robak, E Montserrat, P Ghia, CU Niemann, AP Kater, ...
Annals of Oncology 32 (1), 23-33, 2021
7372021
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long …
G Lenz, M Dreyling, E Hoster, B Wörmann, U Dührsen, B Metzner, ...
Journal of Clinical Oncology 23 (9), 1984-1992, 2005
7132005
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with …
R Forstpointner, M Dreyling, R Repp, S Hermann, A Hänel, B Metzner, ...
Blood 104 (10), 3064-3071, 2004
6972004
Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in …
M Dreyling, G Lenz, E Hoster, A Van Hoof, C Gisselbrecht, R Schmits, ...
Blood 105 (7), 2677-2684, 2005
6572005
The landscape of genomic alterations across childhood cancers
SN Gröbner, BC Worst, J Weischenfeldt, I Buchhalter, K Kleinheinz, ...
Nature 555 (7696), 321-327, 2018
6402018
Treatment of older patients with mantle-cell lymphoma
HC Kluin-Nelemans, E Hoster, O Hermine, J Walewski, M Trneny, ...
New England Journal of Medicine 367 (6), 520-531, 2012
5362012
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
H Tilly, MG Da Silva, U Vitolo, A Jack, M Meignan, A Lopez-Guillermo, ...
Annals of oncology 26, v116-v125, 2015
5262015
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide …
R Forstpointner, M Unterhalt, M Dreyling, HP Böck, R Repp, H Wandt, ...
Blood 108 (13), 4003-4008, 2006
5202006
Improvement of overall survival in advanced stage mantle cell lymphoma
A Herrmann, E Hoster, T Zwingers, G Brittinger, M Engelhard, P Meusers, ...
Journal of Clinical Oncology 27 (4), 511-518, 2009
4652009
Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis
H Schulz, JF Bohlius, S Trelle, N Skoetz, M Reiser, T Kober, G Schwarzer, ...
Journal of the National Cancer Institute 99 (9), 706-714, 2007
4292007
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective …
A Pastore, V Jurinovic, R Kridel, E Hoster, AM Staiger, M Szczepanowski, ...
The lancet oncology 16 (9), 1111-1122, 2015
4112015
Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era
P Pérez-Galán, M Dreyling, A Wiestner
Blood, The Journal of the American Society of Hematology 117 (1), 26-38, 2011
4072011
Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network
M Tiemann, C Schrader, W Klapper, MH Dreyling, E Campo, A Norton, ...
British journal of haematology 131 (1), 29-38, 2005
3812005
Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a …
G Lenz, M Dreyling, E Schiegnitz, R Forstpointner, H Wandt, M Freund, ...
Blood 104 (9), 2667-2674, 2004
3672004
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study
M Dreyling, W Jurczak, M Jerkeman, RS Silva, C Rusconi, M Trneny, ...
The Lancet 387 (10020), 770-778, 2016
3592016
The system can't perform the operation now. Try again later.
Articles 1–20